Telix and Regeneron have entered a strategic partnership valued at $2.1 billion to develop next-generation biologics-based radiopharmaceuticals and radiodiagnostics.
With the agreement, Regeneron will enter the targeted radiopharmaceuticals sphere for the purpose of exploring the utility of its portfolio of antibodies generated from VelocImmune mice, in four initial therapeutic programs, according to Telix.
The collaboration will include multiple solid tumor targets from Regeneron’s portfolio. The companies also plan to develop radiodiagnostics to support patient selection and treatment response assessment.
Telix said it will receive $40 million upfront for allowing Regeneron access to its radiopharmaceutical manufacturing platform. The co-funding and profit-sharing model includes the option for Telix to be eligible to receive up to $535 million in development and commercial milestones for each program, plus low double-digit royalties on net sales.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
